Marvel Biosciences’ MB-204 Shows Promise in Rett Syndrome Study

Marvel Biosciences Corp ( (TSE:MRVL) ) has issued an announcement.

Marvel Biosciences Corp announced promising results from a preclinical study of its lead compound MB-204 for Rett syndrome, conducted with the iBraiN Institute. MB-204 significantly outperformed the currently approved treatment, Trofinetide, in reversing social and behavioral deficiencies in Mecp2 mice, suggesting it could be a promising treatment for Rett Syndrome. The company plans to publish and present the data at a scientific conference.

More about Marvel Biosciences Corp

Marvel Biosciences Corp, along with its subsidiary Marvel Biotechnology Inc, operates in the biotechnology industry. The company focuses on developing innovative treatments for neurological conditions, with its lead compound MB-204 being a primary product.

YTD Price Performance: -10.0%

Average Trading Volume: 33,340

Technical Sentiment Consensus Rating: Sell

Current Market Cap: C$6.05M

See more data about MRVL stock on TipRanks’ Stock Analysis page.